Assertio Therapeutics Announces Amendment of its Senior Secured Credit Facility
“This amendment gives us greater flexibility as we continue to pay down debt and invest in our core business, which will help us build and grow for the future,” said
Revised Covenant Terms:
|Period||Senior Secured Debt Leverage Ratio|
|1st Fiscal Quarter 2019||2.25:1.0|
|2nd and 3rd Fiscal Quarters 2019||2.0:1.0|
|4th Fiscal Quarter 2019||1.75:1.0|
|1st Fiscal Quarter 2020||1.5:1.0|
|2nd Fiscal Quarter 2020||1.25:1.0|
In addition, the Company will add a trailing four-quarter net sales covenant of
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to our loan agreements, including our senior secured debt facility, expectations regarding potential business and investment opportunities and other risks outlined in the Company's public filings with the
Investor and Media Contact:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.